Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | GALNT3 |
| Upstream (Parents) |
|---|
| (<<) CLDN4 → GALNT3 |
| (<<) RAB25 → GALNT3 |
| (<<) EPCAM → GALNT3 |
| Downstream (Children) |
|---|
| GALNT3 → CDCP1 (>>) |
| GALNT3 → EPN3 (>>) |
| GALNT3 → OVOL2 (>>) |
| GALNT3 → FXYD3 (>>) |
| GALNT3 → STYK1 (>>) |
| GALNT3 → CLDN4 (>>) |
| GALNT3 → SLC44A4 (>>) |
| GALNT3 → MUC13 (>>) |
| GALNT3 → GALNT12 (>>) |
| GALNT3 → SMAGP (>>) |
| GALNT3 → C1orf106 (>>) |
| GALNT3 → TSPAN13 (>>) |
| GALNT3 → GALNT7 (>>) |
| GALNT3 → ZDHHC13 (>>) |
| GALNT3 → BCL2L14 (>>) |
| GALNT3 → FAR2 (>>) |
| GALNT3 → BSPRY (>>) |
| GALNT3 → PRR15L (>>) |
| GALNT3 → PIP5K1B (>>) |
| GALNT3 → FA2H (>>) |
| GALNT3 → FUT4 (>>) |
| GALNT3 → XK (>>) |
| GALNT3 → WFDC2 (>>) |
| GALNT3 → POF1B (>>) |
| GALNT3 → CD9 (>>) |
| GALNT3 → PRSS16 (>>) |
| GALNT3 → LILRA1 (>>) |
